[{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"Neonatal Fc receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Not Applicable"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Efgartigimod","moa":"Neonatal Fc receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Halozyme Therapeutics \/ Argenx","highestDevelopmentStatusID":"10","companyTruncated":"Halozyme Therapeutics \/ Argenx"},{"orgOrder":0,"company":"Argenx","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Efgartigimod","moa":"Neonatal Fc receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ argenx","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ argenx"},{"orgOrder":0,"company":"Argenx","sponsor":"Zai Lab","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.17999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Zai Lab","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Zai Lab"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Efgartigimod","moa":"IgG-mediated immune response","graph1":"Immunology","graph2":"Preclinical","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Hansa Biopharma \/ argenx BV","highestDevelopmentStatusID":"4","companyTruncated":"Hansa Biopharma \/ argenx BV"},{"orgOrder":0,"company":"Elektrofi","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Elektrofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elektrofi \/ Argenx","highestDevelopmentStatusID":"10","companyTruncated":"Elektrofi \/ Argenx"},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Not Applicable"},{"orgOrder":0,"company":"Soleo Health","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Approved","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soleo Health \/ Argenx SE","highestDevelopmentStatusID":"12","companyTruncated":"Soleo Health \/ Argenx SE"},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ Not Applicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"Neonatal Fc receptor","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Halozyme Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ Halozyme Therapeutics"},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"Fc receptor","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ Not Applicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"Fc receptor","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ Not Applicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"Fc receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Not Applicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"Neonatal Fc receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Not Applicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"Efgartigimod","moa":"Neonatal Fc receptor","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Medison Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ Medison Pharma"},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"Fc receptor","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ Not Applicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"Fc receptor","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ Not Applicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"FcRn","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ Not Applicable"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Efgartigimod","moa":"Neonatal Fc receptor","graph1":"Immunology","graph2":"Approved","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ Argenx","highestDevelopmentStatusID":"12","companyTruncated":"Fujifilm Diosynth Biotechnologies \/ Argenx"},{"orgOrder":0,"company":"Argenx","sponsor":"USFDA","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Acquisition","leadProduct":"Efgartigimod","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Argenx \/ USFDA","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ USFDA"},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ Not Applicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Not Applicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ Not Applicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ Not Applicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ Not Applicable"},{"orgOrder":0,"company":"Argenx","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Efgartigimod","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0.75,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0.75,"dosageForm":"Infusion","sponsorNew":"Argenx \/ J.P. Morgan","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ J.P. Morgan"},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ Not Applicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Argenx \/ Not Applicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ Not Applicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Zai Lab \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zai Lab \/ Not Applicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Argenx","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Zai Lab \/ argenx","highestDevelopmentStatusID":"14","companyTruncated":"Zai Lab \/ argenx"}]
Find Clinical Drug Pipeline Developments & Deals for Efgartigimod
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
